Claims for Patent: 8,900,565
✉ Email this page to a colleague
Summary for Patent: 8,900,565
Title: | Indole derivatives as inhibitors of histone deacetylase |
Abstract: | Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity. |
Inventor(s): | Buggy; Joseph J. (Moutain View, CA), Balasubramanian; Sriram (San Carlos, CA), Verner; Erik (San Mateo, CA), Tai; Vincent W. F. (San Mateo, CA), Lee; Chang-Sun (Belle Mead, NJ) |
Assignee: | Pharmacyclics, Inc. (Sunnyvale, CA) |
Application Number: | 13/683,880 |
Patent Claims: | 1. A method of alleviating, abating or ameliorating T-cell lymphoma or leukemia in a subject in need thereof, comprising administering to the subject a pharmaceutical
composition containing a therapeutically effective amount of a 1,3-disubstituted-1H-indole-6-carboxylic acid hydroxyamide compound, wherein the substituent at the 1-position is --X.sup.2--R.sup.2 and the substituent at the 3-position is R.sup.3, wherein:
X.sup.2 is a substituted or unsubstituted group selected from among C.sub.2-C.sub.6alkylene, C.sub.1-C.sub.6heteroalkylene; --C(.dbd.O)--, and --C(.dbd.O)--C.sub.1-C.sub.6alkylene; R.sup.2 is a substituted or unsubstituted group selected from among
aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; where if R.sup.2 is substituted, then each substituent on R.sup.2 is selected from among hydrogen, halogen, --CN, --NO.sub.2, --S(.dbd.O).sub.2NH.sub.2, --CO.sub.2H, --CO.sub.2R.sup.10,
--C(.dbd.O)R.sup.11, --S--R.sup.11, --S(.dbd.O)--R.sup.11--S(.dbd.O).sub.2--R.sup.11, --NR.sup.10C(.dbd.O)--R.sup.11, --C(.dbd.O)N(R.sup.10).sub.2, --S(.dbd.O).sub.2N(R.sup.10).sub.2, OC(.dbd.O)N(R.sup.10).sub.2, NR.sup.10C(.dbd.O)O--R.sup.11,
--OC(.dbd.O)O--R.sup.11, --NHC(.dbd.O)NH--R.sup.11, --OC(.dbd.O)--R.sup.11, --N(R.sup.10).sub.2, substituted or unsubstituted C.sub.1-C.sub.6alkyl, substituted or unsubstituted C.sub.2-C.sub.6alkenyl, substituted or unsubstituted C.sub.2-C.sub.6alkynyl,
substituted or unsubstituted C.sub.1-C.sub.6alkoxy, substituted or unsubstituted C.sub.1-C.sub.6heteroalkyl, substituted or unsubstituted C.sub.3-C.sub.8cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl; R.sup.10 is hydrogen, or a substituted or unsubstituted group selected from among C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6heteroalkyl, C.sub.3-C.sub.8cycloalkyl, C.sub.2-C.sub.8heterocycloalkyl, aryl, or heteroaryl; R.sup.11 is a substituted or unsubstituted group selected from among C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.8cycloalkyl, C.sub.2-C.sub.8heterocycloalkyl, aryl, or heteroaryl; R.sup.3 is hydrogen, halogen, substituted or unsubstituted C.sub.1-C.sub.6alkyl,
substituted or unsubstituted C.sub.2-C.sub.6alkenyl, substituted or unsubstituted C.sub.2-C.sub.6alkynyl, substituted or unsubstituted C.sub.1-C.sub.6alkoxy, substituted or unsubstituted C.sub.1-C.sub.6heteroalkyl, substituted or unsubstituted phenyl, or
--X.sup.6--R.sup.6; X.sup.6 is a C.sub.1-C.sub.6alkylene, C.sub.1-C.sub.6fluoroalkylene, C.sub.2-C.sub.6alkenylene, C.sub.2-C.sub.6heteroalkylene; R.sup.6 is hydrogen, halogen, --CN, hydroxy, amino, C.sub.1-C.sub.6alkylamino,
di(C.sub.1-C.sub.6alkyl)amino, C.sub.1-C.sub.6alkoxy, C.sub.3-C.sub.8cycloalkyl, C.sub.2-C.sub.8heterocycloalkyl, phenyl, heteroaryl, or --X.sup.7--R.sup.7 X.sup.7 is a bond, --O--, --S--, --S(.dbd.O)--, --S(.dbd.O).sub.2--, --NR.sup.a--, --C(.dbd.O)--,
--C(.dbd.O)O--, --OC(.dbd.O)--, --NHC(.dbd.O)--, --C(.dbd.O)NR.sup.a--, --S(.dbd.O).sub.2NR.sup.a--, --NHS(.dbd.O).sub.2--, --OC(.dbd.O)NR.sup.a--, --NHC(.dbd.O)O--, --OC(.dbd.O)O--, or --NHC(.dbd.O)NR.sup.a--; R.sup.7 is hydrogen, C.sub.1-C.sub.6alkyl,
C.sub.2-C.sub.6alkenyl, C.sub.1-C.sub.6heteroalkyl, C.sub.1-C.sub.6haloalkyl, C.sub.3-C.sub.8cycloalkyl, cycloalkylalkyl, C.sub.2-C.sub.8heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, R.sup.a is selected from among
hydrogen, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, hydroxy, C.sub.1-C.sub.6alkoxy, C.sub.1-C.sub.6fluoroalkoxy, C.sub.1-C.sub.6heteroalkyl; or R.sup.a and R.sup.7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered
heterocycloalkyl; or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or pharmaceutically acceptable prodrug thereof.
2. The method of claim 1, further comprising administering to the subject a second therapeutic agent, selected from among abarelix (Plenaxis.RTM.); aldesleukin (Prokine.RTM.); Aldesleukin (Proleukin.RTM.); Alemtuzumab (Campath.RTM.); alitretinoin (Panretin.RTM.); allopurinol (Zyloprim.RTM.); altretamine (Hexalen.RTM.); amifostine (Ethyol.RTM.); anastrozole (Arimidex.RTM.); arsenic trioxide (Trisenox.RTM.); asparaginase (Elspar.RTM.); azacitidine (Vidaza.RTM.); bevacizumab (Avastin.RTM.); bexarotene (Targretin.RTM.); bleomycin (Blenoxane.RTM.); bortezomib (Velcade.RTM.); busulfan (Busulfex.RTM.); busulfan (Myleran.RTM.); calusterone (Methosarb.RTM.); capecitabine (Xeloda.RTM.); carboplatin Paraplatin.RTM.); carmustine (BCNU, BiCNU); carmustine (Gliadel.RTM.); celecoxib (Celebrex.RTM.); cetuximab (Erbitux.RTM.); chlorambucil (Leukeran.RTM.); cisplatin (Platinol.RTM.); cladribine (Leustatin.RTM.); clofarabine (Clolar.RTM.); cyclophosphamide (Cytoxan.RTM.); cytarabine (Cytosar-U.RTM.); cytarabine liposomal (DepoCyt); dacarbazine (DTIC-Dome); dactinomycin (actinomycin D, Cosmegen.RTM.); Darbepoetin alfa (Aranesp.RTM.); dasatinib (Sprycel.RTM.); daunorubicin liposomal (DanuoXome); daunorubicin (daunomycin, Daunorubicin.RTM.); daunorubicin (daunomycin, Cerubidine.RTM.); decitabine (Dacogen.RTM.); denileukin (Ontak.RTM.); dexrazoxane (Zinecard.RTM.); docetaxel (Taxotere.RTM.); doxorubicin (Adriamycin.RTM.); doxorubicin liposomnal (Doxil.RTM.); dromostanolone propionate; epirubicin (Ellence.RTM.); Epirubicin; Epoetin alfa (EPOGEN.RTM.); erlotinib (Tarceva.RTM.); estramustine (Emcyt.RTM.); etoposide phosphate (Etopophos.RTM.); etoposide (VP-16; Vepesid.RTM.); exemestane (AROMASIN.RTM.); Filgrastim (Neupogen.RTM.); floxuridine (FUDR); fludarabine (Fludara.RTM.); fluorouracil (5-FU, Adrucil.RTM.); fulvestrant (Faslodex.RTM.), gefitinib (Iressa.TM.); gemcitabine (Gemzar.RTM.); gemtuzumab ozogamicin (Mylotarg.RTM.); goserelin acetate (Zoladex.RTM.); histrelin acetate (Histrelin.RTM.); hydroxyurea (Hydrea.RTM.); Ibritumomab Tiuxetan (Zevalin.RTM.); idarubicin (Idamycin.RTM.); ifosfamide (IFEX.RTM.); imatinib mesylate (Gleevec.RTM.); interferon alfa 2a (Roferon A.RTM.); Interferon alfa-2b (Intron A.RTM.); irinotecan (Camptosar.RTM.); lenalidomide (Revlimid.RTM.); letrozole (Femara.RTM.); leucovorin (Leucovorin.RTM.); Leuprolide Acetate (Eligard.RTM.); levamisole (Ergamisol.RTM.); lomustine, CCNU CeeBU.RTM.); meclorethamine (nitrogen mustard, Mustargen.RTM.); megestrol acetate (Megace.RTM.); melphalan (Alkeran.RTM.); mercaptopurine (6-MP, Purinethol.RTM.); methotrexate (Rheumatrex.RTM., Trexall.RTM.); methoxsalen (Uvadex.RTM.); mitomycin C (Mutamycin.RTM.); mitomycin C (Mitozytrex.RTM.); mitotane (Lysodren.RTM.); mitoxantrone (Novantrone.RTM.); nandrolone phenpropionate (Durabolin-50); nelarabine (Arranon.RTM.); Nofetumomab (Verluma.RTM.); Oprelvekin (Neumega.RTM.); oxaliplatin (Eloxatin.RTM.); paclitaxel (Paxene.RTM.); paclitaxel (Taxol.RTM.); paclitaxel protein-bound particles (Abraxane.RTM.); palifermin (Kepivance.RTM.); pamidronate (Aredia.RTM.); panitumumab (Vectibix.RTM.); pegademase (Adagen.RTM.); pegaspargase (Oncaspar.RTM.); Pegfilgrastim (Neulasta.RTM.); pemetrexed disodium (Alimta.RTM.); pentostatin (Nipent.RTM.); pipobroman (Vercyte.RTM.); plicamycin, mithramycin (Mithracin.RTM.); porfimer sodium (Photofrin.RTM.); procarbazine (Matulane.RTM.); quinacrine (Atabrine.RTM.); Rasburicase (Elitek.RTM.); rituximab (Rituxan.RTM.); sargramostim (Leukine.RTM.); Sargramostim (Prokine.RTM.); sorafenib (Nexavar.RTM.); streptozocin (Zanosar.RTM.); sunitinib maleate (Sutent.RTM.); tamoxifen (Nolvadex.RTM.); temozolomide (Terodar.TM.); teniposide (VM-26, Vumon.RTM.); testolactone (Teslac.RTM.); thalidomide (Thalomid.RTM.); thioguanine (6-TG, Thioguanine.RTM.); thiotepa (Thioplex.RTM.); topotecan (Hycamtin.RTM.); toremifene (Fareston.RTM.); tositumomab (Bexxar.RTM.); tositumomab/I-131 tositumomab (Bexxar.RTM.); trastuzumab (Herceptin.RTM.); tretinoin (ATRA, Vesanoid.RTM.); Uracil Mustard; valrubicin (Valstar.RTM.); vinblastine (Velban.RTM.); vincristine (Oncovin.RTM.): vinorelbine (Navelbine.RTM.); vorinostat (Zolinza.RTM.); zoledronate (Zometa.RTM.); or zoledronic acid (Zometa.RTM.). |
Details for Patent 8,900,565
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2026-03-16 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2026-03-16 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2026-03-16 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.